about
Neutrophil elastase and matrix metalloproteinase 12 in cystic fibrosis lung diseaseEpithelial Anion Transport as Modulator of Chemokine SignalingTherapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug DiscoveryAnimal Models of Cystic Fibrosis Pathology: Phenotypic Parallels and DivergencesNovel Roles for Chloride Channels, Exchangers, and Regulators in Chronic Inflammatory Airway DiseasesRole of Cytokine-Induced Glycosylation Changes in Regulating Cell Interactions and Cell Signaling in Inflammatory Diseases and CancerNovel therapies for the treatment of pertussis diseaseDelivery of ENaC siRNA to epithelial cells mediated by a targeted nanocomplex: a therapeutic strategy for cystic fibrosis.Cellular distribution and function of ion channels involved in transport processes in rat tracheal epithelium.Chronic rhinosinusitis pathogenesis.Synthesis and evaluation of 5,6-disubstituted thiopyrimidine aryl aminothiazoles as inhibitors of the calcium-activated chloride channel TMEM16A/Ano1.ANO1 plays a critical role in prostatic hyperplasia.Airway surface liquid homeostasis in cystic fibrosis: pathophysiology and therapeutic targets.Modulation of TMEM16A channel activity by the von Willebrand factor type A (VWA) domain of the calcium-activated chloride channel regulator 1 (CLCA1).The Lectin-like Domain of TNF Increases ENaC Open Probability through a Novel Site at the Interface between the Second Transmembrane and C-terminal Domains of the α-SubunitFinding new drugs to enhance anion secretion in cystic fibrosis: Toward suitable systems for better drug screening. Report on the pre-conference meeting to the 12th ECFS Basic Science Conference, Albufeira, 25-28 March 2015.New insights into upper airway innate immunity.Airway mucus, inflammation and remodeling: emerging links in the pathogenesis of chronic lung diseases.Rab GTPases regulate the trafficking of channels and transporters - a focus on cystic fibrosis.New perspectives in nanotherapeutics for chronic respiratory diseases.Efficient, non-toxic anion transport by synthetic carriers in cells and epithelia.Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics.Epithelial Chloride Transport by CFTR Requires TMEM16A.Generation and functional characterization of epithelial cells with stable expression of SLC26A9 Cl- channelsTargeting the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Protein for the Treatment of Cystic Fibrosis.Strategies for the etiological therapy of cystic fibrosis.Zinc Deficiency via a Splice Switch in Zinc Importer ZIP2/SLC39A2 Causes Cystic Fibrosis-Associated MUC5AC Hypersecretion in Airway Epithelial Cells.Importance to question sinonasal symptoms and to perform rhinoscopy and rhinomanometry in cystic fibrosis patients.Cytokine-Ion Channel Interactions in Pulmonary Inflammation.Physicochemical properties of mucus and their impact on transmucosal drug delivery.A Protease Inhibitor Tackles Epithelial Sodium Channels in Cystic Fibrosis.Dental treatment for people with cystic fibrosis.The Horizon of a Therapy for Rare Genetic Diseases: A "Druggable" Future for Fibrodysplasia Ossificans Progressiva.Mapping ligand binding pockets in chloride ClC-1 channels through an integrated in silico and experimental approach using anthracene-9-carboxylic acid and niflumic acid.Airway disease phenotypes in animal models of cystic fibrosis.Ion Channel Modulators in Cystic FibrosisRecent advances in developing therapeutics for cystic fibrosisPhysiological and Pathophysiological Relevance of the Anion Transporter Slc26a9 in Multiple Organs
P2860
Q26741691-3F93ED25-B69B-45F3-8290-7914EED10077Q26744381-00C55218-2824-49B5-94D1-6A2784B438AEQ26744730-C8400E70-EE35-436C-9847-36BDAC0485E3Q26747210-044326CF-4A34-4B45-9BEC-1F869EE81B0DQ26776407-3DBEA35A-895A-4A47-A4B1-2F4151525F7CQ28077907-E152951C-8F7A-4ECE-885E-09A4248CA553Q28084039-66EFD998-7DF8-419F-AD5E-2E347F51E153Q33674129-73A4F5C3-6143-41CA-A388-3F17CE9C3DA5Q33856635-77C0E3D1-3A08-4B26-B0ED-D2710B88A540Q35865515-68855AB6-1345-4D07-B012-F8ADE54CF826Q35900576-FE7F0A9F-E359-4ECE-8786-1B18FC6CEE0CQ35946226-9A813AE8-FD74-42B6-8E6A-7E827D1DECCAQ38683678-AAAFF499-47CA-4F77-BBD1-E9C1D3E8F99EQ38707029-B1E5EA40-B4B5-4DB9-8B13-74CC626EDA30Q38744963-6CEE31DB-7AE5-4566-9BB6-C34EA0DAAE6CQ38910094-71B23BAF-895E-468C-9C6D-D2D00CAC1650Q38961660-32488B74-F0F8-477B-AFE5-2A8D2305093CQ39097168-85769477-40DE-4644-A9F3-85904EBD59E3Q39278138-BE5063C1-624B-488F-A8F6-2BE7395F8997Q40039105-44AF3CD1-921D-4DDA-80CF-701167CF25E7Q40206306-F731BFC7-D69D-4233-9B20-6C2E978FAD7AQ40341616-6B0A753B-9E85-48C7-9D15-8633EF399817Q42118445-8A905099-F5F4-4094-8701-F8B15385F8B1Q42121613-CDD09C3C-225C-43FF-A8E3-6345C81F4C2AQ42358777-6E2EB113-6144-4620-B069-33DC1AE87C3AQ42650380-0BE6F0B4-ACEC-4168-90BE-7A295A299AE8Q47208524-00C7C6AB-F3D7-46E7-845E-667135A49C3EQ47614002-A58ECF18-C488-4A86-9612-3E2F94EC98C0Q47651769-F6D1F881-52AE-4572-8669-DF59C304A70FQ47791593-14BFE235-329E-4FCB-96D1-6087C4500ECFQ48355810-C12D6471-B52F-4DE7-BCC1-3AD9BD6F8659Q51527949-D501A600-71BC-4B92-A676-F3B040B54C77Q52340220-3B4EFC3B-3927-4636-A87D-3D2BA9143476Q52676150-22062778-F8FD-4E29-BDF5-626398873E09Q54243366-984C8D59-9DC1-46C9-BD24-B05F2B9C2510Q56966061-B4D6D253-778C-42C8-B798-2744DD6CB48DQ57172314-21B826E6-C39D-4A93-A79E-7FE2FC9D53DBQ58697833-FF90F846-0CAB-4258-960A-0E6D77F625CF
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Targeting ion channels in cystic fibrosis.
@en
type
label
Targeting ion channels in cystic fibrosis.
@en
prefLabel
Targeting ion channels in cystic fibrosis.
@en
P1476
Targeting ion channels in cystic fibrosis.
@en
P2093
Marcus A Mall
P304
P356
10.1016/J.JCF.2015.06.002
P577
2015-06-23T00:00:00Z